Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 284 8891

Website: ateapharma.com

Address:

225 Franklin Street, Suite 2100, Boston, United States

BEATOFtheMARKET Oct. 9 at 3:46 PM

Results of list 9/26/25 $AVGO $AVIR $AVNS $AVNT 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

BOXLinvestor Oct. 9 at 5:37 AM

$AVIR Atea Pharmaceuticals (stock volume 10-08-25) 3.10 +4.4% | volume 1,145,216 | 90-day avg 354,608 × 3.2

0 · Reply

mark31 Oct. 8 at 6:07 PM

$AVIR Atea Pharmaceuticals Insiders Placed Bullish Bets Worth US$5.40M https://finance.yahoo.com/news/atea-pharmaceuticals-insiders-placed-bullish-123525346.html

0 · Reply

mark31 Oct. 8 at 6:02 PM

$AVIR vol here way too cheap

0 · Reply

mark31 Oct. 8 at 5:00 PM

$AVIR added another block at 3

0 · Reply

mark31 Oct. 8 at 3:12 PM

$AVIR

0 · Reply

mark31 Oct. 8 at 3:03 PM

$AVIR nice swings here AVIR and CRDF

0 · Reply

mark31 Oct. 8 at 1:45 PM

$AVIR Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

0 · Reply

mark31 Oct. 8 at 1:41 PM

$AVIR

0 · Reply

mark31 Oct. 8 at 1:41 PM

$AVIR

0 · Reply

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Sep 9, 2025, 5:51 PM EDT - 4 weeks ago

Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 7:00 AM EDT - 5 weeks ago

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 8, 2025, 3:29 PM EDT - 2 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 2 months ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 3 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

May 12, 2025, 4:11 PM EDT - 5 months ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:00 AM EDT - 5 months ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 1, 2025, 7:00 AM EDT - 5 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Apr 23, 2025, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Apr 17, 2025, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Apr 9, 2025, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Mar 31, 2025, 7:04 PM EDT - 6 months ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

Mar 26, 2025, 1:58 PM EDT - 7 months ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Mar 26, 2025, 8:00 AM EDT - 7 months ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 21, 2025, 5:54 PM EDT - 7 months ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 7 months ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 6:14 PM EST - 7 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:05 PM EST - 7 months ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 8 months ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 8 months ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 8, 2025, 7:00 AM EST - 9 months ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 10 months ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 10 months ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 3:14 PM EST - 11 months ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 7:00 AM EST - 11 months ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 11 months ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 11 months ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 9, 2024, 1:14 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Aug 11, 2024, 12:13 PM EDT - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

May 29, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 22, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

May 14, 2024, 10:00 PM EDT - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Mar 27, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Feb 28, 2024, 11:24 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 21, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Jan 8, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Jan 3, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Nov 8, 2023, 6:51 PM EST - 2 years ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:05 PM EST - 2 years ago

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

BEATOFtheMARKET Oct. 9 at 3:46 PM

Results of list 9/26/25 $AVGO $AVIR $AVNS $AVNT 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

BOXLinvestor Oct. 9 at 5:37 AM

$AVIR Atea Pharmaceuticals (stock volume 10-08-25) 3.10 +4.4% | volume 1,145,216 | 90-day avg 354,608 × 3.2

0 · Reply

mark31 Oct. 8 at 6:07 PM

$AVIR Atea Pharmaceuticals Insiders Placed Bullish Bets Worth US$5.40M https://finance.yahoo.com/news/atea-pharmaceuticals-insiders-placed-bullish-123525346.html

0 · Reply

mark31 Oct. 8 at 6:02 PM

$AVIR vol here way too cheap

0 · Reply

mark31 Oct. 8 at 5:00 PM

$AVIR added another block at 3

0 · Reply

mark31 Oct. 8 at 3:12 PM

$AVIR

0 · Reply

mark31 Oct. 8 at 3:03 PM

$AVIR nice swings here AVIR and CRDF

0 · Reply

mark31 Oct. 8 at 1:45 PM

0 · Reply

mark31 Oct. 8 at 1:41 PM

$AVIR

0 · Reply

mark31 Oct. 8 at 1:41 PM

$AVIR

0 · Reply

mark31 Oct. 8 at 1:31 PM

$AVIR

0 · Reply

mark31 Oct. 8 at 1:31 PM

$AVIR in for a swing at 3 has 5 in cash per share

0 · Reply

Cutlass Oct. 7 at 12:17 PM

$AVIR Adding under 2.90 this month - ^

0 · Reply

Thestocktraderhubzee Oct. 7 at 12:12 PM

$AVIR Atea Pharma To Present New Data Supporting Combination Regimen Of Bemnifosbuvir As Potential For HCV Infection Treatment At The Liver Meeting 2025, AASLD

0 · Reply

Cutlass Oct. 7 at 12:09 PM

$AVIR November - 🎉 Atea Pharmaceuticals, Inc. (AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as a potential best-in-class regimen for the treatment of hepatitis C (HCV) infection at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Accepted for presentations were three abstracts detailing multi-scale HCV modeling results and a viral resistance analysis both from the Phase 2 study evaluating the combination regimen of bemnifosbuvir and ruzasvir and results from a Phase 1 study investigating whether there is a food effect with the fixed-dose combination of bemnifosbuvir and ruzasvir. The Liver Meeting 2025 will take place November 7-11 in Washington, DC.

0 · Reply

NVDAMillionaire Sep. 5 at 8:35 PM

$AVIR Outstanding article that hits the mark on AVIR's current state. So if you want to refresh your AVIR insights or learn about AVIR from scratch, this is a must read. https://beyondspx.com/quote/AVIR/atea-pharmaceuticals-pivoting-to-hcv-eradication-with-a-potential-best-in-class-regimen-avir#analysis

0 · Reply

ShadowPath Aug. 23 at 6:25 AM

$AVIR Atea Pharmaceuticals is a antiviral drug developer with clinical stage pipeline and partnership dependencies

0 · Reply

topstockalerts Aug. 19 at 12:09 PM

$AVIR strong watch at these levels

0 · Reply

d_risk Aug. 8 at 2:21 PM

$AVIR - Atea Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors AVIR’s risk factors now spotlight its clinical-stage status, SUNRISE-3 trial failure and COVID-19 program halt, mounting R&D costs, expanded US manufacturing focus, new strategic collaboration and financing risks, detailed regulatory and trial hurdles, increased cybersecurity and privacy threats, ESG and climate change pressures, and new risks tied to analyst coverage and exclusive legal forums. #ClinicalStage #ESGPressure #CybersecurityThreats #RegulatoryRisks #RAndDCosts 🟢 Added 🟠 Removed https://d-risk.ai/AVIR/10-Q/2025-08-07

0 · Reply

NVDAMillionaire Jul. 29 at 6:52 PM

$AVIR Brilliant piece that captures AVIR's situation perfectly. So if you want to update your understanding of AVIR or get to know AVIR better, this is essential reading. https://beyondspx.com/article/atea-pharmaceuticals-pivoting-to-hcv-eradication-with-a-potential-best-in-class-regimen-avir

0 · Reply

satsandstocks Jul. 26 at 4:02 AM

$AVIR - Monthly - beautiful if it closes this way. Anyone know of any upcoming catalyst?

0 · Reply

Cutlass Jul. 25 at 6:54 PM

$AVIR Hard bounce off 2.50 📈👍

0 · Reply

Market Cap	249.18M
Revenue (ttm)	0.00
Net Income (ttm)	-168.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	360,000
Avg Vol	340,922
Day's Range	N/A - N/A
Shares Out	79.36M
Stochastic %K	93%
Beta	0.22
Analysts	Sell
Price Target	$6.00